


PTO/SB/08 Equivalent

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

 INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	09/662,454
	Filing Date	September 14, 2000
	First Named Inventor	Yanagi et al.
	Art Unit	1633
(Multiple sheets used when necessary)	Examiner	Marvich, Maria
SHEET 1 OF 2	Attorney Docket No.	NIH258.001DV1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹


NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
mm	1	Yu M-YW, Bartosch B, Zhang P, Guo Z-P, Renzi PM, Shen L-M, Granier C, Feinstone SM, Cosset F-L, Purcell RH. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. <i>PNAS USA</i> 2004;101(20):7705-7710.	
	2	Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, Emerson SU, Cosset FL, Purcell RH, Bukh J. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. <i>PNAS USA</i> 2005;102(12):4560-4565.	
	3	Bassett, SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, Lanford RE. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. <i>Hepatology</i> 2001;33:1479-1487.	
	4	Major ME, Mihalik K, Puig M, Rehmann B, Nascimbeni M, Rice CM, Feinstone SM. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. <i>Journal of Virology</i> 2002;76(13):6586-6595.	
	5	Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, Ray SC, Thomas DL. Cross-genotype immunity to hepatitis C virus. <i>Journal of Virology</i> 2004;78(3):1575-1581.	
	6	Weiner AJ, Paliard X, Selby MJ, Medina-Selby A, Coit D, Nguyen S, Kansopon J, Arian CL, Ng P, Tucker J, Lee CT, Polakos NK, Han J, Wong S, Lu HH, Rosenberg S, Brasky KM, Chien D, Kuo G, Houghton M. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. <i>Journal of Virology</i> 2001;75(15):7142-7148.	
	7	Bukh J, Thimme R, Satterfield WC, Meunier JC, Spangenberg HC, Forns X, Chang KM, Emerson SU, Chisari FV, Purcell RH. Persistence of HCV after homologous monoclonal re-challenge is associated with emergence of virus variants. In Jilbert AR, Grgacic EVL, Vickery K, Burrell CJ, Cossart YE, eds. <i>Proceedings of the 11th International Symposium on Viral Hepatitis & Liver Disease</i> . Australian Centre for Hepatitis Virology 2004:375-377.	
mm	8	Yanagi M, Purcell RH, Emerson SU, Bukh J. Hepatitis C virus: An infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. <i>Virology</i> 1999;262(1):250-263.	

Examiner Signature	<i>M Marvich</i>	Date Considered	<i>11/21/06</i>
--------------------	------------------	-----------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.



PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary)	Application No.	09/662,454
	Filing Date	September 14, 2000
	First Named Inventor	Yanagi et al.
	Art Unit	1633
SHEET 2 OF 2	Examiner	Marvich, Maria
	Attorney Docket No.	NIH258.001DV1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
MM	9	Okamoto H, Mishiro S, Tokita H, Tsuda F, Miyakawa Y, Mayumi M. Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a. <i>Hepatology</i> 1994;20:1131-1136.	
	10	Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, Purcell RH, Chisari FV. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. <i>PNAS USA</i> 2002;99(24):15661-15668.	
	11	Major ME, Dahari H, Mihalik K, Puig M, Rice CM, Neumann AU, Feinstone S. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. <i>Hepatology</i> 2004;39(6):1709-1720.	
	12	Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. <i>Journal of Virology</i> 2001;75(15):7059-7066.	
MM	13	Su A, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV. Genomic analysis of the host response to hepatitis C virus infection. <i>PNAS USA</i> 2002;99(24):15669-15674.	

2914871
091106

Examiner Signature <i>Marvich</i>	Date Considered <i>11/21/06</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.